Recent Updates
Recently added Catalysts

Antithrombin III Deficiency: one US-listed biotech with a clinical-stage programme

Rare Genetic & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$2.1Buniverse median $1.20B
Allocated capital$1.0B$2.1B competing
Phase 3 or filed01 mid, 0 early
Pure plays0this indication only
Capital rank152/299crowding rank 166

Antithrombin III Deficiency is uncontested. Grifols, S.A. Sponsored ADR (GRFS) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with Plasma-derived AT-III in phase 2.

There is no public comparable to price it against. GRFS spreads its $2.1B market cap across 2 indications, so $1.0B of it is allocated here.

Nothing here has reached Phase 3: 1 programme in mid stage and 0 in early stage, so the field is still several years from a first approval.

$1.0B of allocated capital sits in Antithrombin III Deficiency, ranking it 152nd of 299 indications by the money committed to it.

Companies developing drugs for Antithrombin III Deficiency 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
GRFSGrifols, S.A. Sponsored ADRPlasma-derived AT-IIIPhase 21$2.1BNo2 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Antithrombin III Deficiency counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Antithrombin III Deficiency has one competitor and a median of $2.1B.

Rare Genetic & Metabolic

Rare Genetic & Metabolic holds $103B of the map's capital, 15.3% of the total, spread across 32 indications and 48 companies. 10 of those indications have more than one company competing.

See every Rare Genetic & Metabolic indication on the map

Related indications in Rare Genetic & Metabolic

Von Willebrand Disease1 company · $1.0B · median $2.1BUncontestedCongenital FVII Deficiency1 company · $1.0B · median $2.1BUncontestedMECP2 Duplication Syndrome1 company · $1.1B · median $9.7BUncontestedAcquired Angioedema1 company · $1.2B · median $2.3BUncontestedLimb-Girdle Muscular Dystrophy1 company · $809M · median $2.4BUncontestedMucopolysaccharidosis Type IIIA1 company · $729M · median $3.6BUncontestedLate-onset Pompe Disease1 company · $729M · median $3.6BUncontestedSanfilippo Syndrome (MPS IIIB)2 companies · $654M · median $815MOrphan corner

Antithrombin III Deficiency pipeline questions

Which biotech companies are developing drugs for Antithrombin III Deficiency?

Grifols, S.A. Sponsored ADR (GRFS, Plasma-derived AT-III, Phase 2). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Antithrombin III Deficiency.

How advanced is the Antithrombin III Deficiency pipeline?

Of the 1 clinical-stage programme in Antithrombin III Deficiency, 0 are in Phase 3 or filed, 1 is in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Antithrombin III Deficiency?

No. GRFS is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Antithrombin III Deficiency, which is why the indication is classified as uncontested.

When is the next Antithrombin III Deficiency catalyst?

The next dated catalyst in Antithrombin III Deficiency is GRFS on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map